GCG and Hypoglycemia: The results of a few pilot studies indicated a lower amount of insulin needed to gain similar (or even better) glycemic control using a DPP-4 inhibitor or a GLP-1 agonist in combination with the insulin therapy and also significantly less time spent in hypoglycemia when the GLP-1 agonist Liraglutide therapy was applied with insulin in T1DM patients with residual β-cell function [147, 148].